Bottleneck
Late and uneven diagnosis
Many people receive a dementia diagnosis late, or never receive a subtype. That blocks both care planning and trial entry.
Bottleneck
Trial populations that skip mixed disease
Antibody trials largely enrolled people with biomarker-supported Alzheimer’s disease and excluded much mixed, vascular, and diverse disease.
Bottleneck
Unpaid care as the hidden delivery system
Most day-to-day dementia care is unpaid. Medicines and scans fail in practice if one person is carrying every task alone.
Bottleneck
Wrong-subtype treatment
Lewy body, vascular, and frontotemporal dementia are still treated as if they were typical Alzheimer’s disease, which can add harm.